



HAN Update – COVID-19 Vaccine update: Extended dosing intervals | February

24, 2022 – shepherd@docshepherd.com – docshepherd.com Mail

<https://mail.google.com/mail/u/0/?shva=1#inbox/FMfcgzGmvBtHFKhNsCvMRSdcvVPLcljx?projector=1&messagePartId=0.1>

Key points

- On February 22, 2022, CDC updated the interim clinical considerations for use of COVID-19 vaccines to include an extended interval between the first and second doses of mRNA (Pfizer and Moderna) COVID-19 vaccines for some individuals. Full details are available at <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series>.
- Some studies in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than four weeks.
- An eight-week interval between the first and second dose of mRNA (Pfizer and Moderna) COVID-19 vaccines may be optimal for some people ages 12 years and older, especially for males ages 12-39 years.
- The recommendations for people with moderate to severe immunocompromise have not changed.
- A three- or four-week interval between the first and second doses of mRNA (Pfizer and Moderna) COVID-19 vaccines continues to be the recommended interval for people who are moderately to severely immunocompromised, adults ages 65 years and older, and others who need rapid protection due to increased concern about community transmission or risk of severe disease.